BR112014016450A2 - composto antagonista de leucotrieno b4 - Google Patents

composto antagonista de leucotrieno b4

Info

Publication number
BR112014016450A2
BR112014016450A2 BR112014016450A BR112014016450A BR112014016450A2 BR 112014016450 A2 BR112014016450 A2 BR 112014016450A2 BR 112014016450 A BR112014016450 A BR 112014016450A BR 112014016450 A BR112014016450 A BR 112014016450A BR 112014016450 A2 BR112014016450 A2 BR 112014016450A2
Authority
BR
Brazil
Prior art keywords
pharmaceutically acceptable
compound
formula
acceptable salt
leukotriene
Prior art date
Application number
BR112014016450A
Other languages
English (en)
Inventor
Richard Stack Douglas
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112014016450A2 publication Critical patent/BR112014016450A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo patente de invenção: "composto antagonista de leucotrieno b4". a presente invenção refere-se a um composto da fórmula (i): ou um sal farmaceuticamente aceitável deste. também, a presente invenção fornece uma composição farmacêutica compreendendo um composto da fórmula (i) ou um sal farmaceuticamente aceitável deste e um carregador farmaceuticamente aceitável. a presente invenção fornece ainda métodos para tratar aneurisma aórtico abdominal ou aterosclerose compreendendo administrar uma quantidade terapeuticamente eficaz de um composto da fórmula (i) ou um sal farmaceuticamente aceitável deste ou uma composição farmacêutica compreendendo um carregador farmaceuticamente aceitável e uma quantidade terapeuticamente eficaz de um composto da fórmula (i) ou sal farmaceuticamente aceitável deste. 21705567v1
BR112014016450A 2012-01-10 2013-01-04 composto antagonista de leucotrieno b4 BR112014016450A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261584975P 2012-01-10 2012-01-10
US201261585799P 2012-01-12 2012-01-12
PCT/US2013/020195 WO2013106238A1 (en) 2012-01-10 2013-01-04 Leukotriene b4 antagonist compound

Publications (1)

Publication Number Publication Date
BR112014016450A2 true BR112014016450A2 (pt) 2019-09-24

Family

ID=47604162

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014016450A BR112014016450A2 (pt) 2012-01-10 2013-01-04 composto antagonista de leucotrieno b4

Country Status (14)

Country Link
US (1) US9187411B2 (pt)
EP (1) EP2802557B1 (pt)
JP (1) JP2015509917A (pt)
KR (1) KR20140099546A (pt)
CN (1) CN104011012B (pt)
AU (1) AU2013208260A1 (pt)
BR (1) BR112014016450A2 (pt)
CA (1) CA2857521C (pt)
EA (1) EA023067B1 (pt)
ES (1) ES2571452T3 (pt)
IN (1) IN2014MN01014A (pt)
MX (1) MX2014008452A (pt)
WO (1) WO2013106238A1 (pt)
ZA (1) ZA201404732B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10336733B2 (en) 2015-11-30 2019-07-02 Merk Sharp & Dohme Corp. Aryl acylsulfonamides as BLT1 antagonists
US10370368B2 (en) 2015-11-30 2019-08-06 Merck Sharp & Dohme Corp. Aryl acylsulfonamides as BLT1 antagonists
EP3383868B1 (en) 2015-11-30 2022-10-05 Merck Sharp & Dohme LLC Aryl sulfonamides as blt1 antagonists
US10450309B2 (en) 2015-11-30 2019-10-22 Merch Sharp & Dohme Corp. Aryl sulfonamides as BLT1 antagonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5105017A (en) * 1983-07-18 1992-04-14 Eli Lilly And Company Leukotriene antagonist intermediates
GB9027023D0 (en) 1990-12-12 1991-01-30 Wellcome Found Anti-atherosclerotic aryl compounds
PH30449A (en) 1991-11-25 1997-05-28 Lilly Co Eli Substituted phenyl phenol leukotriene antagonists
CN1035001C (zh) * 1993-01-02 1997-05-28 伊莱利利公司 取代的苯基苯酚基白三烯拮抗物
AU5857296A (en) 1995-05-17 1996-11-29 Eli Lilly And Company Use of leukotriene antagonists for alzheimer's disease
AU6572298A (en) 1997-03-21 1998-10-20 Eli Lilly And Company Leukotriene antagonists useful for treating ischemia reperfusion injury
WO2001034198A2 (en) 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
AU2041801A (en) 1999-11-11 2001-06-06 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
EP1326605A4 (en) 2000-05-09 2004-03-17 Univ Creighton METHODS FOR INHIBITING PROLIFERATION AND INDUCING APOPTOSIS IN CANCER CELLS
JP2003535856A (ja) * 2000-06-02 2003-12-02 イーライ リリー アンド カンパニー ベンゾイル置換二環式化合物およびキラルベンゾピラン誘導体の調製方法
CN1751037A (zh) 2003-02-14 2006-03-22 伊莱利利公司 作为ppar调节剂的磺酰胺衍生物

Also Published As

Publication number Publication date
JP2015509917A (ja) 2015-04-02
IN2014MN01014A (pt) 2015-07-03
EA201491099A1 (ru) 2014-11-28
WO2013106238A1 (en) 2013-07-18
AU2013208260A1 (en) 2014-06-05
EP2802557B1 (en) 2016-04-06
MX2014008452A (es) 2014-08-27
EP2802557A1 (en) 2014-11-19
CN104011012B (zh) 2016-01-20
CA2857521A1 (en) 2013-07-18
EA023067B1 (ru) 2016-04-29
CN104011012A (zh) 2014-08-27
US9187411B2 (en) 2015-11-17
ZA201404732B (en) 2015-11-25
ES2571452T3 (es) 2016-05-25
KR20140099546A (ko) 2014-08-12
US20140343151A1 (en) 2014-11-20
CA2857521C (en) 2016-03-01

Similar Documents

Publication Publication Date Title
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112015016911A2 (pt) tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201390917A1 (ru) Дигетероарильные соединения в качестве ингибиторов vps34
BR112013030894A2 (pt) moduladores do sistema imune
BR112013019256A2 (pt) inibição de il-17 e ifn-gama para o tratamento de inflamação autoimune
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
MX349159B (es) Derivados deuterados de ivacaftor.
BR112014010420A2 (pt) inibidores de pak para o tratamento de distúrbios proliferativos celulares
MX345238B (es) (aralquilamino y heteroarilalquilamino alfa-substituidos)pirimidin ilo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas.
BR112014006271A2 (pt) composições farmacêuticas
PH12014502218A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
BR112013026361A2 (pt) derivados de glicosídeo e usos dos mesmos
MX2012013879A (es) Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
TN2014000031A1 (en) Use of organic compound for the treatment of noonan syndrome
BR112014016450A2 (pt) composto antagonista de leucotrieno b4

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.